Literature DB >> 6865505

Possible role of neuromelanin in the pathogenesis of Parkinson's disease.

D M Mann, P O Yates.   

Abstract

The numbers of nerve cells in the substantia nigra and locus caeruleus were counted, and the volume of their nucleolus and the amount of neuromelanin pigment they contain measured, in patients with Parkinson's disease and in age-matched and elderly individuals free from neurological illness. The number of pigmented nerve cells of both types is reduced by about 20% in the elderly when compared with age-matched controls. The melanin content of the remaining cells in the elderly is lessened (by 11% in substantia nigra and 21% in locus caeruleus) in such a way as to indicate that this age depletion in cell number results from a preferential loss of those nerve cells which contain the greatest amounts of melanin pigment. In Parkinson's disease there is a greater overall reduction in the amount of melanin within remaining cells (15% in substantia nigra, 25% in locus caeruleus) because of a more severe (80%) loss of the heavier pigmented cells. The basis for Parkinson's disease may therefore lie with an aggravation, possibly by secondary factors, of changes that occur within neurones of substantia nigra and locus caeruleus as part of their "normal" process of ageing.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6865505     DOI: 10.1016/0047-6374(83)90074-x

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  33 in total

1.  Correlation between neuromelanin-sensitive MR imaging and (123)I-FP-CIT SPECT in patients with parkinsonism.

Authors:  Keita Kuya; Yuki Shinohara; Fuminori Miyoshi; Shinya Fujii; Yoshio Tanabe; Toshihide Ogawa
Journal:  Neuroradiology       Date:  2016-01-16       Impact factor: 2.804

Review 2.  Proteomics of the human brain: sub-proteomes might hold the key to handle brain complexity.

Authors:  F Tribl; K Marcus; G Bringmann; H E Meyer; M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  2006-07-13       Impact factor: 3.575

Review 3.  Neuromelanin of the human substantia nigra: an update.

Authors:  Fabio A Zucca; Emy Basso; Francesca A Cupaioli; Emanuele Ferrari; David Sulzer; Luigi Casella; Luigi Zecca
Journal:  Neurotox Res       Date:  2013-10-24       Impact factor: 3.911

4.  Determinants of autonomic dysfunction in idiopathic Parkinson's disease.

Authors:  Alexei Korchounov; Kirn R Kessler; Nikolay N Yakhno; Igor V Damulin; Hayo I Schipper
Journal:  J Neurol       Date:  2005-12       Impact factor: 4.849

5.  Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease.

Authors:  F C Cheng; J S Kuo; L G Chia; G Dryhurst
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 6.  Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.

Authors:  Rainer Knörle
Journal:  Neurotox Res       Date:  2017-09-06       Impact factor: 3.911

7.  Neurotoxicity due to o-quinones: neuromelanin formation and possible mechanisms for o-quinone detoxification.

Authors:  F Solano; V J Hearing; J C García-Borrón
Journal:  Neurotox Res       Date:  2000-02       Impact factor: 3.911

8.  Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease.

Authors:  Tomás González-Hernández; Ignacio Cruz-Muros; Domingo Afonso-Oramas; Josmar Salas-Hernandez; Javier Castro-Hernandez
Journal:  Front Neuroanat       Date:  2010-10-20       Impact factor: 3.856

9.  The progression of idiopathic Parkinson's disease is not explained by age-related changes. Clinical and pathological comparisons with post-encephalitic parkinsonian syndrome.

Authors:  W R Gibb; A J Lees
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

10.  Neuromelanin Modulates Heterocyclic Aromatic Amine-Induced Dopaminergic Neurotoxicity.

Authors:  Vivek Lawana; Se Young Um; Jean-Christophe Rochet; Robert J Turesky; Jonathan H Shannahan; Jason R Cannon
Journal:  Toxicol Sci       Date:  2020-01-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.